New Data Support Roflumilast Cream in Infants with Eczema at 3 Months of Age, With Lawrence Eichenfield, MD

New Data Support Roflumilast Cream in Infants with Eczema Over 4 Weeks, With Lawrence Eichenfield, MD

Roflumilast cream .05% (Zoryve) has demonstrated meaningful efficacy and a favorable safety profile among infants with mild to moderate atopic dermatitis as young as 3 months, according to new data.

These phase 2 data were presented during a late-breaking podium session at the 

2026 American Academy of Dermatology (AAD) Annual Meeting

 in Denver, adding new information to the growing body of evidence behind roflumilast cream for infants aged 3 months to less than 24 months with mild to moderate disease. To discuss these data, 

 spoke at AAD with Lawrence Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children's Hospital-San Diego and professor of dermatology and pediatrics at the UC San Diego School of Medicine.

“It had been studied, as you pointed out, in that four week time period, once a day over four weeks,” Eichenfield said. “It was nice that they could do it in a short period of time and show the difference from the vehicle and show efficacy.”

Eichenfield, the presenting author of the INTEGUMENT-INFANT data, opened his discussion by framing the study within the longstanding limitations of topical drugs in this vulnerable patient population. Continuous use of topical corticosteroids is not appropriate for young children, he noted, and even intermittent utilization requires careful management of quantity and frequency.

In this open-label trial, during which 101 infants were evaluated when using roflumilast cream .05% over 4 weeks, there were 96 participants who completed treatment. Eichenfield and colleagues found 34.4% attained validated Investigator Global Assessment (IGA) success and 49% attained a score of clear or almost clear by the fourth week. The team found scalp involvement, present at baseline in 40 of these infants, improved well, with 67.5% showing clearance success at the 4-week mark.

On the Eczema Area and Severity Index (EASI), 58.3% of these participants achieved at least 75% improvement by Week 3, with 34% already attaining this level at Week 2. Eichenfield et al also highlighted the notable caregiver-reported itch outcomes, with more than 72% of infants showing meaningful itch improvement by the 4-week mark, and nearly half showing at least a 25% improvement in their itch level within just 10 minutes of application.

This was a result Eichenfield noted directly in his presentation remarks as evidence of rapid relief for both infants and their families. In terms of safety, roflumilast cream’s profile was described as reassuring and consistent with what was seen in the older INTEGUMENT-PED cohort. There were no serious adverse events observed, as only 1 individual discontinued due to an adverse event. Additionally, at least 97.9% of infants had no application site irritation throughout the analysis.

Arcutis has announced its plans to submit a supplemental New Drug Application (sNDA) for roflumilast cream .05% in infants aged 3 months to less than 24 months in the second quarter of 2026.

Disclosures: Eichenfield previously reported receiving personal fees from Pfizer Inc; grant funding from AbbVie, Arcutis Biotherapeutics, Bausch + Lomb, Castle Biosciences, Dermavant Sciences Inc, Galderma SA, Pfizer Inc, Regeneron, and Sanofi SA and consulting for ASLAN Pharmaceuticals, AbbVie, Almirall, SA, Arcutis Biotherapeutics, Arena Pharmaceuticals Inc, Dermavant Sciences Inc, Galderma SA, Incyte Corporation, LEO Pharma A/S, Eli Lilly and Company, Ortho Dermatologics, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi SA, and UCB; and serving on the board of directors of Forté Pharma.

Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting. Arcutis. March 28, 2026. 

https://www.globenewswire.com/de/news-release/2026/03/28/3264182/0/en/Arcutis-Presents-New-Phase-2-Results-in-Infants-with-Atopic-Dermatitis-in-Late-Breaking-Session-Today-at-the-2026-American-Academy-of-Dermatology-Annual-Meeting.html

Smith T. Positive Topline Data Released on Roflumilast Cream in Infants with Atopic Dermatitis. HCPLive. February 2, 2026. Accessed March 28, 2026. 

https://www.hcplive.com/view/positive-topline-data-released-roflumilast-cream-infants-atopic-dermatitis

Videos

This AAD interviews covers new, late-breaking findings on roflumilast cream 0.05% (Zoryve) in infants with mild‑to‑moderate atopic dermatitis.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

Risankizumab (Skyrizi; AbbVie) demonstrated significantly greater skin clearance than deucravacitinib (Sotyktu; Bristol Myers Squibb) at week 16 across a broad range of patient subgroups in adults with biologic-naïve moderate plaque psoriasis, according to a subgroup analysis of the phase 4 IMMpactful trial presented at the 

 held in Denver, Colorado, from March 27-31.¹

The results extend the primary efficacy findings of IMMpactful — first reported at the Fall Clinical Dermatology Conference in October 2025 — to subgroup populations defined by age, sex, race, smoking status, BMI, baseline disease severity, and presence of psoriatic arthritis.¹

IMMpactful (NCT06333860) is an Abbvie-funded, ongoing phase 4, multicenter, randomized, open-label, efficacy assessor-blinded study comparing risankizumab with deucravacitinib in adults with moderate plaque psoriasis. Eligible patients had a body surface area involvement of 10–15%, a PASI score ≥12, and a static Physician Global Assessment (sPGA) score of 3, and had not previously received biologic therapy. Patients were randomized 1:2 to subcutaneous risankizumab 150 mg at baseline and week 4 (n = 131) or oral deucravacitinib 6 mg once daily (n = 262) for the initial 16-week period. Co-primary endpoints were PASI 90 and sPGA 0/1 at week 16. The study is ongoing, with 52-week data anticipated at a future congress.¹

Baseline demographics were comparable between arms. Mean age was 47.3 versus 44.8 years, mean PASI was 15.7 versus 15.3, and mean affected BSA was 13.2% versus 13.0% in the risankizumab and deucravacitinib groups, respectively.¹

Investigator Nina Magnolo, MD, Professor of Dermatology and Neurodermatology at the University Hospital Münster, and colleagues found that in the overall population, risankizumab achieved significantly higher rates of PASI 90 (57.3% vs 22.9%), sPGA 0/1 (80.2% vs 39.7%), and PASI 100 (27.5% vs 6.5%) compared with deucravacitinib at week 16, all at 

The subgroup analysis at AAD 2026 examined whether this advantage was consistent across clinically relevant patient characteristics. Across nearly all subgroups examined, risankizumab maintained a statistically significant advantage on both PASI 90 and sPGA 0/1.¹

For PASI 90, differences favoring risankizumab reached statistical significance (

 ≤.05) in patients under 40 years (77.8% vs 18.2%), those aged 40 to <65 years (54.5% vs 21.8%), White patients (58.1% vs 22.8%), non-White patients (50.0% vs 24.3%), male patients (60.0% vs 23.8%), female patients (53.8% vs 23.3%), current smokers (59.5% vs 22.1%), previous or never smokers (56.2% vs 23.2%), all three BMI categories, patients with baseline PASI above the median of 14.4 (52.8% vs 21.6%), patients with baseline PASI at or below the median (69.0% vs 23.3%), and patients without psoriatic arthritis (55.7% vs 23.3%).¹

The one subgroup where statistical significance was not reached was patients aged ≥65 years — though the proportion numerically favored risankizumab (77.8% vs 31.8%); the authors attributed this to the small sample size in that age stratum.¹ Similarly, in the small psoriatic arthritis subgroup (n = 9 risankizumab, n = 22 deucravacitinib), the PASI 90 difference was numerically but not statistically significant (47.1% vs 18.2%).¹

The sPGA 0/1 results followed a parallel pattern, with risankizumab achieving statistically significant superiority (

 ≤.01) across all subgroups except patients aged ≥65 years.¹

Safety through week 16, previously reported at the Fall Clinical Dermatology Conference, was consistent with the established profiles of both agents.¹

IMMpactful is among the first prospective head-to-head randomized trials directly comparing an IL-23 inhibitor with a TYK2 inhibitor in psoriasis, addressing a gap that has previously required indirect methods. A 2024 matching-adjusted indirect comparison (MAIC) published in 

 analyzed data from the UltIMMa-1 and UltIMMa-2 risankizumab trials and the POETYK PSO-1 and PSO-2 deucravacitinib trials, finding significantly higher rates of PASI 75, PASI 90, PASI 100, and DLQI 0/1 with risankizumab at both 16 and 52 weeks.² The IMMpactful direct comparison now provides prospective data in a moderate psoriasis population that MAICs cannot fully capture.

The mechanistic distinction between the 2 agents is relevant to interpreting the magnitude of the difference. Risankizumab selectively blocks the p19 subunit of IL-23, interrupting upstream cytokine signaling that drives Th17-mediated skin inflammation. Deucravacitinib allosterically inhibits TYK2, a kinase involved in signaling downstream of IL-12, IL-23, and type I interferon receptors — a broader mechanism that does not achieve the same degree of IL-23 pathway selectivity. Whether the differential PASI 90 and PASI 100 rates at week 16 are sustained or narrow over longer follow-up will be a key question when 52-week IMMpactful data are presented later this year.¹

Magnolo N, Soung J, Sivamani RK, et al. Risankizumab vs deucravacitinib in adults with moderate plaque psoriasis: week 16 subgroup results from the IMMpactful study. Poster presented at: 2026 American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, CO. Poster DV-017716.

Armstrong AW, Soliman AM, Gisondi P, et al. Matching-adjusted indirect comparison of risankizumab versus deucravacitinib in patients with moderate to severe plaque psoriasis. 

 2024;14(11):3071–3081. doi:10.1007/s13555-024-01293-y

Articles

The IMMpactful direct comparison provides prospective data in a moderate psoriasis population that previous MAICs could not fully capture.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Risankizumab Outperforms Deucravacitinib on Psoriasis Clearance Across Patient Subgroups in Phase 4 Head-to-Head Trial

Vlado Perkovic is Dean and Scientia Professor of Medicine at UNSW Sydney. He is also a Professorial Fellow at The George Institute and a Staff Specialist in Nephrology at the Royal North Shore Hospital in Sydney.

Kidney Compass: New 2-Year APPLAUSE-IgAN Data for Iptacopan at WCN 2026

The treatment landscape for IgA nephropathy (IgAN) continues to evolve at a rapid pace, and new data presented at the World Congress of Nephrology (WCN) in Yokohama, Japan, suggest a potential shift in how clinicians approach disease modification in high-risk patients. In this episode of 

, hosts Shikha Wadhwani, MD, MS, and Brendon Neuen, MBBS, PhD, spoke with Vlado Perkovic, MBBS, PhD, about newly presented 2-year eGFR slope data from the phase 3 APPLAUSE-IgAN trial evaluating iptacopan.

Perkovic explained that the trial built on previously published findings in the 

 showing a 38% reduction in proteinuria at 9 months, but emphasized that the key question remained whether this would translate into long-term kidney protection. As he noted during the discussion, the study enrolled a particularly high-risk population, with median proteinuria around 1.7 g/g and rapid progression in the placebo arm—where eGFR declined by more than 6 mL/min/1.73 m² per year. Both hosts highlighted how this rate of decline reinforced the urgency for new therapies.

According to Perkovic, treatment with iptacopan slowed that decline to just over 3 mL/min/1.73 m² annually, representing an approximately 50% reduction compared with placebo and a treatment effect that exceeded initial expectations. Wadhwani and Neuen both pointed to this magnitude of benefit as especially compelling, particularly given that the trial was powered for a much smaller difference. Perkovic further noted that the key secondary composite endpoint, 30% eGFR decline or kidney failure, was reduced by 43%, which the hosts emphasized as evidence that the slope findings are likely to translate into meaningful clinical outcomes.

Safety was another focal point of the conversation. Perkovic noted that adverse events, serious adverse events, and discontinuations were comparable between groups, with no deaths reported. While he acknowledged a numerical increase in infections with iptacopan, he emphasized that all cases were manageable and resolved with treatment, and there was no concerning signal for severe or encapsulated infections.

The discussion then shifted to how iptacopan might fit into an increasingly complex treatment paradigm. Wadhwani raised the question of where complement inhibition would sit alongside existing therapies and evolving guideline recommendations, prompting Perkovic to stress that foundational treatments such as renin-angiotensin system inhibitors and SGLT2 inhibitors remain essential. However, he noted that patients receiving SGLT2 inhibitors in the trial still derived clear additional benefit, supporting the idea of combination therapy.

Neuen also highlighted the importance of understanding eGFR slope dynamics, asking whether acute versus chronic effects might influence interpretation of treatment benefit. In response, Perkovic explained that, unlike some other therapies, iptacopan did not appear to have an acute hemodynamic effect on eGFR, resulting in a more linear and interpretable slope over time, a point both hosts noted could simplify comparisons across agents.

Looking ahead, all three speakers emphasized the likelihood that combination approaches will be necessary, particularly for patients with high baseline proteinuria. As Perkovic pointed out during the exchange, achieving guideline-recommended targets may require multiple therapies with complementary mechanisms. Wadhwani further stressed the importance of earlier diagnosis and intervention, while Perkovic suggested that evolving data may prompt clinicians to reconsider biopsy thresholds and treatment timing.

Editors’ Note: Relevant disclosures for 

 include AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, and others. Relevant disclosures for

include Boehringer Ingelheim, Calliditas Therapeutics, GSK, Otsuka Pharmaceutical Co., Travere Therapeutics, and others. Relevant disclosures for

include Boehringer Ingelheim,AbbVie, Inc., Bristol-Myers Squibb, servier, Astellas Pharma US, Merck, Janssen Pharmaceuticals, GSK, and others.

Podcasts

Vlado Perkovic, MBBS, PhD, discusses APPLAUSE-IgAN data showing iptacopan reduced eGFR decline and lowered kidney event risk in IgA nephropathy.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Kidney Compass: Navigating Clinical Trials

Hosted by Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, Kidney Compass: Navigating Clinical Trials is a regular podcast exploring and breaking down the latest updates and nuances of clinical trials in nephrology. By listening to Kidney Compass, you'll get the guidance you need to navigate the changing landscape of clinical trials across the spectrum of kidney disease. 

Hiddo Heerspink, PharmD, PhD, is a professor of Clinical Trials and Personalized Medicine, clinical trialist at the Department of Clinical Pharmacy and Pharmacology at the University Medical Center Groningen.

Kidney Compass: ASSIST Trial Shows Atrasentan Benefit on Top of SGLT2 Inhibitors

As the treatment landscape for IgA nephropathy grows increasingly complex, new data presented at the World Congress of Nephrology 2026 in Yokohama, Japan, are beginning to clarify how emerging therapies may work together. 

, hosts Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, sat down with Hiddo Heerspink, PhD, PharmD, to discuss the phase 2 ASSIST trial, which evaluated the efficacy and safety of atrasentan in combination with SGLT2 inhibitors.

Throughout the discussion, Heerspink emphasized that the trial was intentionally designed to address a rapidly evolving standard of care. As he explained, growing evidence supporting SGLT2 inhibitors in chronic kidney disease, specifically in IgA nephropathy, prompted the need to understand whether additional therapies like atrasentan could provide incremental benefit when layered on top. Neuen and Wadhwani both highlighted this rationale, framing the study as a forward-looking effort to anticipate real-world combination therapy.

To efficiently generate these data, Heerspink noted that the investigators used a randomized, placebo-controlled crossover design, allowing each patient to serve as their own control. As Neuen pointed out during the conversation, this approach improves statistical efficiency and reduces the required sample size. The study enrolled 51 patients, each receiving atrasentan and placebo sequentially on top of background SGLT2 inhibition, with both short-term (12-week) and longer-term (24-week) treatment periods incorporated into the design.

Wadhwani underscored another key distinction raised by Heerspink: the inclusion of patients with lower levels of proteinuria, starting at 0.5 g/day. According to Heerspink, this decision, made before the latest guideline updates, allowed the trial to explore efficacy in a broader, earlier-stage population than many prior phase 3 studies. Both hosts noted how this aligns with a growing emphasis on earlier diagnosis and intervention in IgA nephropathy.

In presenting the results, Heerspink stated that atrasentan reduced proteinuria by approximately 25% compared with placebo when added to SGLT2 inhibitors, with effects apparent by 12 weeks and sustained through 24 weeks. He further emphasized that the drug did not produce an acute decline in eGFR, challenging longstanding assumptions about endothelin receptor antagonists, and that its effects on blood pressure were modest.

Safety was a central focus of the discussion. Heerspink highlighted concerns around fluid retention with this class of agents but noted that, in ASSIST, these risks were minimal when atrasentan was combined with SGLT2 inhibitors. Both Neuen and Wadhwani pointed to the reassuring safety signals, including stable body weight and no clinically meaningful changes in biomarkers, reinforcing Heerspink’s conclusion that the combination appears both safe and well tolerated.

Looking beyond the trial, the conversation turned to broader implications for clinical practice and research design. Wadhwani raised the potential for crossover studies to help individualize therapy, prompting Heerspink to suggest that such designs could offer insight into patient-specific responses. However, he cautioned that variability in proteinuria measurements must be carefully considered when interpreting individual-level changes.

Heerspink additionally challenged the conventional sequencing of therapies. As he explained during the episode, the order in which drugs are developed should not dictate how they are used in practice. Instead, he advocated for a more pathophysiology-driven approach, tailoring treatment selection and sequencing to disease mechanisms and stage rather than defaulting to historical standards of care.

 include AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Inc., Chinook Therapeutics Inc., Gilead Sciences, Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Travere Therapeutics, and others. Relevant disclosures for 

 include AstraZeneca, Bayer, Boehringer and Ingelheim, Janssen, and others. Relevant disclosures for 

include the National Institute of Diabetes and Digestive and Kidney Diseases, GSK, Calliditas and Travere Therapeutics.

Hiddo Heerspink, MD, PhD, highlights ASSIST trial data showing atrasentan reduced proteinuria by 25% on top of SGLT2 inhibitors in IgA nephropathy.

Swapnil Hiremath, MD, MPH, is a Staff Nephrologist at the Ottawa Hospital, a Professor in the Faculty of Medicine, cross appointed to the School of Epidemiology and Public Heath at the University of Ottawa, and also an Associate Scientist in the Clinical Epidemiology Programme at the Ottawa Hospital Research Institute.

Bridging the Gap in Hypertension Care Delivery, With Swapnil Hiremath, MD, MPH

Hypertension remains one of the most consequential but uncontrolled drivers of global morbidity and mortality. Affecting more than 1 billion people worldwide, it is the leading modifiable risk factor for death, contributing to millions of preventable deaths each year.

Despite the availability of effective, low-cost therapies, blood pressure control rates have stagnated or even declined in many regions, highlighting a critical gap not in knowledge, but in implementation. Programs like the World Health Organization’s Global HEARTS Initiative aim to close this gap by focusing on scalable, system-level solutions.

 at at the World Congress of Nephrology (WCN) Conference in Yokohama, Japan, Swapnil Hiremath, MD, MPH, a nephrologist at the Ottawa Hospital and professor at the University of Ottawa, emphasized that the challenge is not a lack of effective treatments, but rather the failure to consistently apply simple, evidence-based strategies in real-world settings.

“Even if you look at high income countries, BP control is hard, and sometimes we don't do the simple things well,” Hiremath said.

He notes that even modest reductions in blood pressure can yield substantial benefits, including meaningful decreases in cardiovascular events, stroke, heart failure, and overall mortality. However, these gains are often unrealized due to fragmented care systems, limited access to medications, and clinical inertia.

The HEARTS framework, he explains, is designed to address these barriers through a comprehensive yet practical approach. Built around key pillars including healthy lifestyle counseling, standardized treatment protocols, access to essential medications, risk-based management, team-based care, and systems for monitoring, HEARTS prioritizes feasibility and adaptability across diverse healthcare settings.

Hiremath notes that a central component of this approach is the emphasis on affordability and accessibility. He highlights the strategic use of widely available, low-cost medications such as calcium channel blockers, angiotensin receptor blockers, and thiazide diuretics, therapies selected not only for efficacy, but also for their safety profiles and minimal need for laboratory monitoring, which are critical considerations in low-resource environments where access to follow-up care may be limited.

He also underscores the importance of team-based care models, which enable non-physician providers to follow structured treatment algorithms and escalate therapy efficiently. This approach helps overcome workforce limitations and reduces delays in treatment intensification, a common contributor to poor blood pressure control.

While the program has made meaningful progress, reaching tens of millions of individuals across dozens of countries, Hiremath notes that this represents only a fraction of the global burden. Expanding implementation will require sustained political commitment, local adaptation, and continued focus on health system strengthening.

“The solutions are there. We don't have to invent a vaccine, we don't need new technology, we don't need any fancy drugs,” he said. “We have the tools, it's just about implementation.”

Editors’ Note: Hiremath reports no relevant disclosures.

Farrar J, Frieden T. WHO global report on hypertension 2025. The Lancet. doi:

World Health Organization. Global Hearts Initiative. Accessed March 29, 2026. 

https://www.who.int/initiatives/global-hearts-initiative

Hypertension drives millions of preventable deaths, yet control lags globally. The HEARTS framework offers practical, scalable solutions to close this gap.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

CAR-T therapy shows potential for deep, durable remission in lupus nephritis, but questions remain on safety, durability, and patient selection.

Can CAR-T Cell Therapy Transform Lupus Nephritis Care? With Brad Rovin, MD

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

A subgroup analysis of VESALIUS-CV suggests evolocumab could have a role in prevention of primary events in some high-risk patients.

Dyslipidemia

Atherosclerotic Cardiovascular Disease

Type 2 Diabetes

VESALIUS-CV: Evolocumab Cuts First MACE Risk in Diabetes Without Atherosclerosis

New data from the KARDINAL trial at ACC.26 provides insight, but raises questions regarding tonlamarsen and hypertension. 

Monthly Tonlamarsen Reduces Angiotensinogen, But No Significant Difference in Blood Pressure

Amy Sarma, MD, is the Cathy E. Minehan Endowed Chair in Cardiology and co-director of the Corrigan Women’s Heart Health Program and Cardiovascular Disease and Pregnancy Programs at the Massachusetts General Hospital.

Sarma discusses the ongoing movement to highlight the different cardiovascular risks facing women, particularly during the most turbulent periods of life.

Strategic Alliance Partnership

Combatting Cardiovascular Risk in Postpartum and Menopausal Women, With Amy Sarma, MD

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

These 52-week, phase 3 data on icotrokinra, presented at AAD, highlight the drug's efficacy and safety among adults with moderate to severe plaque psoriasis.

Sustained Itch Reduction Observed at 1 Year of Icotrokinra in Psoriasis, With Linda Stein Gold, MD

The findings extend the radiographic dataset for risankizumab in PsA to 244 weeks — the longest such follow-up reported from the KEEPsAKE program.

KEEPsAKE-1: Risankizumab Maintains Radiographic Nonprogression Through 5 Years in Psoriatic Arthritis

Rosmarin discussed new late-breaking data from ADVANCE-AA at AAD 2026.

Alopecia

First in Class Rezpegaldesleukin: Favorable Safety, Durable Responses in Alopecia Areata, With David Rosmarin, MD 

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

This late-breaking, phase 2 data highlights nemolizumab's clinically meaningful benefits for children with moderate-to-severe atopic dermatitis.

Late-Breaking Data Highlight Nemolizumab Efficacy in Children with Atopic Dermatitis

HI-PEITHO concluded use of ultrasound-facilitated catheter-directed fibrinolysis improves pulmonary embolism outcomes. 

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Latest News

New Data Support Roflumilast Cream in Infants with Eczema Over 4 Weeks, With Lawrence Eichenfield, MD

Risankizumab Outperforms Deucravacitinib on Psoriasis Clearance Across Patient Subgroups in Phase 4 Head-to-Head Trial

Kidney Compass: New 2-Year APPLAUSE-IgAN Data for Iptacopan at WCN 2026

Kidney Compass: ASSIST Trial Shows Atrasentan Benefit on Top of SGLT2 Inhibitors

Bridging the Gap in Hypertension Care Delivery, With Swapnil Hiremath, MD, MPH